Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Head & Neck 1Gynecologic 1Genitourinary 1

Conditions

Breast Neoplasms 75Neoplasm Metastasis 12Neoplasms 8Ovarian Neoplasms 6Endometrial Neoplasms 6Pancreatic Neoplasms 5Carcinoma, Renal Cell 5Sarcoma 4Neoplasms by Site 4Lymphoma, Non-Hodgkin 4Breast Diseases 4Squamous Cell Carcinoma of Head and Neck 3Multiple Myeloma 3Lymphoma 3Lung Neoplasms 3Liposarcoma 3Kidney Neoplasms 3Head and Neck Neoplasms 3Glioma 3Wilms Tumor 2Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Recurrence 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2

Interventions

Cisplatin 6pembrolizumab 5Nivolumab 5palbociclib 4durvalumab 4Pemetrexed 4atezolizumab 3abemaciclib 3Fulvestrant 3Carboplatin 3Anastrozole 3130-nm albumin-bound paclitaxel 3selpercatinib 2ribociclib 2relatlimab 2entrectinib 2cobimetinib 2capmatinib 2alectinib 2Vemurafenib 2Radiosurgery 2Paclitaxel 2Letrozole 2Gonadotropin-Releasing Hormone 2Gemcitabine 2Bevacizumab 2AZD9833 2trametinib 1taletrectinib 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Neoplasms by Site × palbociclib × 1 year × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT04964934 2026-04-21

SERENA-6

AstraZeneca

Phase 3 Active not recruiting
315 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site

NCT05935748 2025-11-12

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

NiKang Therapeutics, Inc.

Phase 2 Terminated
18 enrolled
Genitourinary

Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT04711252 2025-10-14

SERENA-4

AstraZeneca

Phase 3 Active not recruiting
1,370 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Skin Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡